Cowen & Co. analyst Chris Shibutani reiterated a Buy rating on Agios Pharma (NASDAQ: AGIO) today. The company’s shares opened today at $68.87.
According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 3.2% and a 39.7% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Pieris Pharmaceuticals, Nektar Therapeutics, and United Therapeutics.
Agios Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $83.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $99.82 and a one-year low of $51.62. Currently, Agios Pharma has an average volume of 440.2K.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is neutral on the stock. Most recently, in September 2018, David Schenkein, the CEO of AGIO bought 8,730 shares for a total of $276,217.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
